Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 11, 2019 08:30 ET | Source: Espero BioPharma

Espero BioPharma Announces Tecarfarin Receives FDA Orphan Drug Designation for Patients with End Stage Renal Disease and Atrial Fibrillation

JACKSONVILLE, Fla. and IRVINE, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- Espero BioPharma, Inc., a pharmaceutical company focused on the development of therapeutics for unmet needs in thrombosis...
January 24, 2019 11:00 ET | Source: Espero BioPharma

Espero BioPharma Provides Update on the Development of Tecarfarin for the Treatment of Mechanical Heart Valve Patients in China

JACKSONVILLE, Fla. and IRVINE, Calif., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Espero BioPharma, Inc., a pharmaceutical company focused on the development of late-stage drugs for unmet needs in thrombosis...
October 09, 2018 09:00 ET | Source: Espero Biopharma

Espero BioPharma Appoints Lee Golden, M.D., as Chief Medical Officer

JACKSONVILLE, Fla. and IRVINE, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Espero BioPharma, Inc., (“Espero”, or “the Company”), a pharmaceutical company focused on the development of late-stage drugs...
May 30, 2018 09:00 ET | Source: Espero Biopharma

Espero BioPharma to Present at the 2018 BIO International Convention, Wednesday, June 6, 2018

JACKSONVILLE, Fla., May 30, 2018 (GLOBE NEWSWIRE) -- Espero BioPharma, Inc., (the “Company”) a biopharmaceutical company focusing on the late-stage development and commercialization of drugs to...
January 03, 2018 08:30 ET | Source: Espero Biopharma

Espero BioPharma to Present at Biotech Showcase on January 9, 2018

JACKSONVILLE, Fla. and IRVINE, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Espero BioPharma, a biopharmaceutical company focusing on the late-stage development and commercialization of drugs to treat...
December 12, 2017 08:30 ET | Source: Espero Biopharma

Espero BioPharma Provides Corporate Update and 2018 Objectives

- Pivotal Phase 3 trial for tecarfarin under FDA-approved Special Protocol Assessment provides clear regulatory pathway to the $8.5 billion U.S. oral anticoagulant market - JACKSONVILLE, Fla. and...